Varenicline and nicotine enhance GABAergic synaptic transmission in rat CA1 hippocampal and medial septum/diagonal band neurons

The FDA approved smoking cessation aid varenicline can effectively attenuate nicotine-stimulated dopamine release. Varenicline may also exert important actions on other transmitter systems that also influence nicotine reinforcement or contribute to the drug's cognitive and affective side effect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Life sciences (1973) 2013-03, Vol.92 (6-7), p.337-344
Hauptverfasser:	DuBois, Dustin W., Damborsky, Joanne C., Fincher, Annette S., Frye, Gerald D., Winzer-Serhan, Ursula H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Addiction adverse effects agonists Animals antagonists Basal forebrain Benzazepines - pharmacology CA1 Region, Hippocampal - drug effects CA1 Region, Hippocampal - physiology cognition Cognitive function Dependence dopamine drugs Female GABA release GABAergic Neurons - drug effects GABAergic Neurons - physiology gamma-aminobutyric acid Hippocampus Inhibitory Postsynaptic Potentials - drug effects Inhibitory Postsynaptic Potentials - physiology Male memory mIPSC Neural Inhibition - drug effects Neural Inhibition - physiology neurons Neurons - physiology nicotine Nicotine - pharmacology Nicotinic Agonists - pharmacology patch-clamp technique Patch-Clamp Techniques - methods Quinoxalines - pharmacology Rats Rats, Sprague-Dawley Septal Nuclei - drug effects Septal Nuclei - physiology synaptic transmission Synaptic Transmission - drug effects Synaptic Transmission - physiology Varenicline
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!